A Toronto-based biotech company is co-sponsoring a trial to treat front-line clinicians who are experiencing COVID-19 distress with psychedelic-assisted psychotherapy.
Cybin announced the randomized, placebo-controlled trial earlier this week. The study will aim to treat symptoms of depression, anxiety, burnout and post-traumatic stress among front-line doctors, nurses and healthcare professionals.
The trial will be hosted in Seattle and in collaboration with the University of Washington. Dr. Anthony Back, a professor of medicine and founding co-director of the University of Washington Center for Excellence in Palliative Care, will lead the study.
“There is tremendous potential in a collaboration between the University of Washington and Cybin to move the field forward, and this project is an incredibly valuable initial step towards a productive future,” said Dr. Back.
As part of its role in the trial, Cybin developed EMBARK, a transdiagnostic psychotherapy model that can be
Read full article on The Growth Op